ArticleTherapeutic innovation & regulatory science2026
RWE Submission for European Regulators and Payers: Challenges, Uncertainties, and Opportunities.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 28.Journal of comparative effectiveness research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new European Union Joint Clinical Assessment (JCA) process, effective January 2025, requires pharmaceutical companies to submit evidence within 100 days of notification. Key challenges include uncertainty about PICO (Population, Intervention, Comparator, Outcomes) parameters prior to PICO notification, limited timeframe for evidence generation, and need to reconcile differences between regulatory versus health technology assessment (HTA) evidence standards. Uncertainties involve predicting PICOs accurately and determining real-world evidence's (RWE) appropriate role. However, opportunities exist for integrated evidence planning across clinical development, regulatory, and health economics and outcomes research (HEOR) teams, leveraging real-world data to inform or address PICOs as well as support regulatory evidence requirements. Early alignment between key functional teams, combined with proactive RWE use, is essential for generating fit-for-purpose evidence that satisfies the dual scrutiny of regulatory approval and HTA relative effectiveness assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.